This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Jul 2016

Pfizer receives FDA approval for Prevnar 13 in adults age 18 through 49

Prevnar 13 is the only pneumococcal vaccine approved in the US for patients 6 weeks through adulthood.

Pfizer has announced that Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) has received FDA approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes. Prevnar 13 is the only pneumococcal vaccine approved across the lifespan.

Prevnar 13 is now approved for

  • Adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains in the vaccine
  • Children 6 weeks through 17 years of age (prior to the 18th birthday) for the prevention of invasive disease caused by 13 Streptococcus pneumoniae strains in the vaccine.
  • The expanded age indication now more closely aligns with the 2012 US Centers for Disease Control and Prevention’s Advisory Committee on Immunizations Practices (ACIP) recommendations for adults 19 years of age and older with immunocompromising conditions (e.g., HIV, chronic renal failure, cancer), functional or anatomic asplenia (e.g., sickle cell disease), cerebral spinal fluid leak, and Cochlear implants. This is in addition to recommendations set forth by ACIP in 2014 for adults 65 years and older.

    “This expanded age indication in adults 18 to 49 offers an important public health benefit as appropriate vaccination against S. pneumoniae is critical to reducing the risk of pneumococcal disease, including in those with immunocompromising conditions," said Dr Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines.

    The FDA’s decision to approve the label expansion followed the submission and review of data from an open-label, Phase III trial of Prevnar 13 in adults who were not previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The study, which was published in Vaccine in October 2015, compared the immunogenicity, safety, and tolerability of Prevnar 13 in adults age 18 to 49 years with adults age 60 to 64, for whom Prevnar 13 was already approved.

    Related News